ESCMID*  ||| S:0 E:8 ||| NNP
guideline  ||| S:8 E:18 ||| NN
for  ||| S:18 E:22 ||| IN
the  ||| S:22 E:26 ||| DT
diagnosis  ||| S:26 E:36 ||| NN
and  ||| S:36 E:40 ||| CC
management  ||| S:40 E:51 ||| NN
of  ||| S:51 E:54 ||| IN
Candida  ||| S:54 E:62 ||| NNP
diseases  ||| S:62 E:71 ||| VBD
2012 ||| S:71 E:75 ||| CD
:  ||| S:75 E:77 ||| :
patients  ||| S:77 E:86 ||| NNS
with  ||| S:86 E:91 ||| IN
HIV  ||| S:91 E:95 ||| NNP
infection  ||| S:95 E:105 ||| NN
or  ||| S:105 E:108 ||| CC
AIDS  ||| S:108 E:113 ||| NNP
Mucosal  ||| S:113 E:121 ||| NNP
candidiasis  ||| S:121 E:133 ||| NN
is  ||| S:133 E:136 ||| VBZ
frequent  ||| S:136 E:145 ||| JJ
in  ||| S:145 E:148 ||| IN
immunocompromised  ||| S:148 E:166 ||| JJ
HIV-infected  ||| S:166 E:179 ||| NN
highly  ||| S:179 E:186 ||| RB
active  ||| S:186 E:193 ||| JJ
antiretroviral  ||| S:193 E:208 ||| NNS
( ||| S:208 E:209 ||| -LRB-
HAART ||| S:209 E:214 ||| NNP
)  ||| S:214 E:216 ||| -RRB-
naive  ||| S:216 E:222 ||| JJ
patients  ||| S:222 E:231 ||| NNS
or  ||| S:231 E:234 ||| CC
those  ||| S:234 E:240 ||| DT
who  ||| S:240 E:244 ||| WP
have  ||| S:244 E:249 ||| VBP
failed  ||| S:249 E:256 ||| VBN
therapy ||| S:256 E:263 ||| NN
.  ||| S:263 E:265 ||| .
Mucosal  ||| S:265 E:273 ||| JJ
candidiasis  ||| S:273 E:285 ||| NN
is  ||| S:285 E:288 ||| VBZ
a  ||| S:288 E:290 ||| DT
marker  ||| S:290 E:297 ||| NN
of  ||| S:297 E:300 ||| IN
progressive  ||| S:300 E:312 ||| JJ
immune  ||| S:312 E:319 ||| JJ
deficiency ||| S:319 E:329 ||| NN
.  ||| S:329 E:331 ||| .
Because  ||| S:331 E:339 ||| IN
of  ||| S:339 E:342 ||| IN
the  ||| S:342 E:346 ||| DT
frequently  ||| S:346 E:357 ||| RB
marked  ||| S:357 E:364 ||| VBN
and  ||| S:364 E:368 ||| CC
prompt  ||| S:368 E:375 ||| VB
immune  ||| S:375 E:382 ||| JJ
reconstitution  ||| S:382 E:397 ||| JJ
induced  ||| S:397 E:405 ||| NN
by  ||| S:405 E:408 ||| IN
HAART ||| S:408 E:413 ||| NNP
,  ||| S:413 E:415 ||| ,
there  ||| S:415 E:421 ||| EX
is  ||| S:421 E:424 ||| VBZ
no  ||| S:424 E:427 ||| DT
recommendation  ||| S:427 E:442 ||| NN
for  ||| S:442 E:446 ||| IN
primary  ||| S:446 E:454 ||| JJ
antifungal  ||| S:454 E:465 ||| JJ
prophylaxis  ||| S:465 E:477 ||| NN
of  ||| S:477 E:480 ||| IN
mucosal  ||| S:480 E:488 ||| JJ
candidiasis  ||| S:488 E:500 ||| NN
in  ||| S:500 E:503 ||| IN
the  ||| S:503 E:507 ||| DT
HIV  ||| S:507 E:511 ||| NNP
setting  ||| S:511 E:519 ||| NN
in  ||| S:519 E:522 ||| IN
Europe ||| S:522 E:528 ||| NNP
,  ||| S:528 E:530 ||| ,
although  ||| S:530 E:539 ||| IN
it  ||| S:539 E:542 ||| PRP
has  ||| S:542 E:546 ||| VBZ
been  ||| S:546 E:551 ||| VBN
evidenced  ||| S:551 E:561 ||| VBN
as  ||| S:561 E:564 ||| IN
effective  ||| S:564 E:574 ||| JJ
in  ||| S:574 E:577 ||| IN
the  ||| S:577 E:581 ||| DT
pre-HAART  ||| S:581 E:591 ||| JJ
era ||| S:591 E:594 ||| NN
.  ||| S:594 E:596 ||| .
Fluconazole  ||| S:596 E:608 ||| NNP
remains  ||| S:608 E:616 ||| VBZ
the  ||| S:616 E:620 ||| DT
first  ||| S:620 E:626 ||| JJ
line  ||| S:626 E:631 ||| NN
of  ||| S:631 E:634 ||| IN
therapy  ||| S:634 E:642 ||| NN
for  ||| S:642 E:646 ||| IN
both  ||| S:646 E:651 ||| DT
oropharyngeal  ||| S:651 E:665 ||| JJ
candidiasis  ||| S:665 E:677 ||| NN
and  ||| S:677 E:681 ||| CC
oesophageal  ||| S:681 E:693 ||| JJ
candidiasis  ||| S:693 E:705 ||| NN
and  ||| S:705 E:709 ||| CC
should  ||| S:709 E:716 ||| MD
be  ||| S:716 E:719 ||| VB
preferred  ||| S:719 E:729 ||| VBN
to  ||| S:729 E:732 ||| TO
itraconazole  ||| S:732 E:745 ||| VB
oral  ||| S:745 E:750 ||| JJ
solution  ||| S:750 E:759 ||| NN
( ||| S:759 E:760 ||| -LRB-
or  ||| S:760 E:763 ||| CC
capsules  ||| S:763 E:772 ||| NNS
when  ||| S:772 E:777 ||| WRB
not  ||| S:777 E:781 ||| RB
available ||| S:781 E:790 ||| JJ
)  ||| S:790 E:792 ||| -RRB-
due  ||| S:792 E:796 ||| JJ
to  ||| S:796 E:799 ||| TO
fewer  ||| S:799 E:805 ||| JJR
side  ||| S:805 E:810 ||| NN
effects ||| S:810 E:817 ||| NNS
.  ||| S:817 E:819 ||| .
For  ||| S:819 E:823 ||| IN
patients  ||| S:823 E:832 ||| NNS
who  ||| S:832 E:836 ||| WP
still  ||| S:836 E:842 ||| RB
present  ||| S:842 E:850 ||| VB
with  ||| S:850 E:855 ||| IN
fluconazole-refractory  ||| S:855 E:878 ||| JJ
mucosal  ||| S:878 E:886 ||| JJ
candidiasis ||| S:886 E:897 ||| NN
,  ||| S:897 E:899 ||| ,
oral  ||| S:899 E:904 ||| JJ
treatment  ||| S:904 E:914 ||| NN
with  ||| S:914 E:919 ||| IN
any  ||| S:919 E:923 ||| DT
other  ||| S:923 E:929 ||| JJ
azole  ||| S:929 E:935 ||| NN
should  ||| S:935 E:942 ||| MD
be  ||| S:942 E:945 ||| VB
preferred  ||| S:945 E:955 ||| VBN
based  ||| S:955 E:961 ||| VBN
on  ||| S:961 E:964 ||| IN
precise  ||| S:964 E:972 ||| JJ
Candida  ||| S:972 E:980 ||| JJ
species  ||| S:980 E:988 ||| JJ
identification  ||| S:988 E:1003 ||| NN
and  ||| S:1003 E:1007 ||| CC
susceptibility  ||| S:1007 E:1022 ||| JJ
testing  ||| S:1022 E:1030 ||| NN
results  ||| S:1030 E:1038 ||| NNS
in  ||| S:1038 E:1041 ||| IN
addition  ||| S:1041 E:1050 ||| NN
to  ||| S:1050 E:1053 ||| TO
the  ||| S:1053 E:1057 ||| DT
optimization  ||| S:1057 E:1070 ||| NN
of  ||| S:1070 E:1073 ||| IN
HAART  ||| S:1073 E:1079 ||| NNP
when  ||| S:1079 E:1084 ||| WRB
feasible ||| S:1084 E:1092 ||| JJ
.  ||| S:1092 E:1094 ||| .
For  ||| S:1094 E:1098 ||| IN
vaginal  ||| S:1098 E:1106 ||| JJ
candidiasis ||| S:1106 E:1117 ||| NN
,  ||| S:1117 E:1119 ||| ,
topical  ||| S:1119 E:1127 ||| JJ
therapy  ||| S:1127 E:1135 ||| NN
is  ||| S:1135 E:1138 ||| VBZ
preferred ||| S:1138 E:1147 ||| VBN
.  ||| S:1147 E:1149 ||| .
